Market Place
Sourcing Support
All News #Library
Biotech
Kazia Pays Research Institute $1.4M For Epigenetic Platform
14 Apr 2026 //
FIERCE BIOTECH
Kazia Pharma Expands Oncology With First-In-Class SETDB1 Platform
13 Apr 2026 //
PR NEWSWIRE
Kazia`s Nuclear PD-L1 Degrader: Preclinical & Translational Data
30 Jan 2026 //
PR NEWSWIRE BIO
Kazia Shows Positive Early Results In Phase 1B Paxalisib Study
27 Jan 2026 //
PR NEWSWIRE
Kazia Pharma Showcases Paxalisib`s Anti-Tumor Immunity Boost
10 Dec 2025 //
PR NEWSWIRE
Kazia Therapeutics Hits Initial iCR in Metastatic TNBC
19 Nov 2025 //
PR NEWSWIRE
Kazia’s Paxalisib Combo Shows 86% Tumor Drop in Metastatic TNBC
02 Oct 2025 //
PR NEWSWIRE
Kazia Backs Australian MRFF funded Project For AI-Driven DIPG/DMG
01 Oct 2025 //
PR NEWSWIRE
Kazia Paxalisib Disrupts Stage IV Breast Cancer Cells
11 Sep 2025 //
PR NEWSWIRE
Kazia Sees >50% Tumor Drop In Paxalisib Combo Trial
09 Jul 2025 //
PR NEWSWIRE
Kazia Therapeutics Reveals Paxalisib`s Potential in TNBC
11 Jun 2025 //
PR NEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.